Catherine's career began at Institut Curie, a leading institute in Oncology, as molecular biology researcher. Following this experience and a business degree, she joined Ile de France Innovation, an incubator, where she assisted several Biotech and MedTech companies in their development.
Joining CapDecisif Management in 2003, Catherine is the Managing Partner in charge of the Healthcare portfolio. She is involved in the overall management of the firm, particularly involved in fundraising activities and investors relations.
Catherine is investing in Healthcare and Digital Health ventures, and represents CapDecisif Management at the board of several portfolio companies such as Acticor Biotech, Eyevensys, Tricares, Vitamfero and WatchFrog. Catherine was investor and board member of Echosens (acquired by Furui Group), DBV Technologies (Listed on Nasdaq : DBV), Erytech Pharma (Listed on Nasdaq : ERYP), Nanobiotix (Listed on Euronext : NANO), Voluntis (Listed on Euronext : VTX).
Catherine holds an MSc in Molecular Biology from University Pierre and Marie Curie (Paris) and graduated in Innovation Management from AgroParis Tech.